Ben Beckley, Global Lead at EmerGENE explores the market challenges holding back Cell and Gene Therapy (C>) from taking its place as an established treatment area. He explains how we can navigate obstacles to ensure C> can achieve its full potential. As a treatment area, C> has shown robust growth in recent years. Some 3,366 treatments are currently in preclinical and clinical development[1]. The global market is projected to reach $13.8 billion by 2026 from $7.7 billion in 2021, at a CAGR of 12.4% throughout the forecast period[2]. There are several reasons for this growth, including high global cancer rates,
The post How can we fulfill the promise of Cell and Gene Therapy? appeared first on Pharma Mirror Magazine.
